Bleeding from oesophageal varices, oesophageal ulcers or oesophagitis is occasionally massive and difficult to control. Octreotide, a synthetic analogue of somatostin lowers portal pressure and collateral blood flow including that through varices, increases lower oesophageal sphincter pressure, and inhibits the gastric secretion of acid as well as pepsin. Our current experience suggests it is effective in controlling acute variceal haemorrhage. Therefore we have examined the efficacy of octreotide in the control of postsclerotherapy bleeding from oesophageal varices, oesophageal ulcers and oesophagitis. During the study period 77 patients experienced a significant gastrointestinal bleed (blood pressure < 100 mm Hg, pulse > 100 beats per min or the need to transfuse 2 or more units of blood to restore the haemoglobin level) following injection sclerotherapy of oesophageal varices. The source of bleeding was varices in 42 patients, oesophageal ulcers in 31 and oesophagitis in 4. All patients received a continuous intravenous infusion of octreotide (50 lag/h) for between 40-140h. If bleeding was not controlled in the first 12h after commencing octreotide hourly bolus doses (50 lag) for 24 h were superimposed on the continuous infusion. Haemorrhage was successfully controlled by an infusion of octreotide in 38 of the 42 patients with bleeding from varices, in 30 of 31 patients with oesophageal ulceration, and all patients with oesophagitis. In the patient with persistent bleeding from oesophageal ulceration and in 2 of the 4 with continued haemorrhage from varices, haemostasis was achieved by hourly boluses of 50 lag octreotide for 24h in addition to the continuous infusion. No major complications were associated with octreotide administration. The results of this study clearly indicate that octreotide is a safe and effective treatment for the control of severe haemorrhage after technically successful injection sclerotherapy.
INTRODUCTION
Injection sclerotherapy is an effective treatment for the control of acute variceal bleeding and for subsequent obliteration of the varices. Localised rebleeding following injection sclerotherapy of oesophageal varices can occur from 3 sources, the varices themselves, oesophageal ulcers and oesophagitis. Persistent recurrent bleeding from the varices following injection sclerotherapy is often substantial, and is independently associated with a poorer prognosis1. In contrast, bleeding from oesophageal ulcers or oesophagitis after injection sclerotherapy is usually minor, but can occasionally be massive and difficult to control. We have recently demonstrated that somatostatin is a very effective and safe treatment for the control of recurrent bleeding following injection sclerotherapy from the varices2, oesophageal ulcers and oesophagitis3. Octreotide, a synthetic analogue of somatostatin, has similar effects as the native hormone on portal pressure4, azygos blood flow 5'6 intravariceal pressure7, the gastric secretion of pepsin and acid and on lower oesophageal sphincter pressure9. These 
RESULTS

Recurrent variceal bleeding
During the study period a total of 744 courses of sclerotherapy were carried out, 225 to control an acute variceal bleed and 519 electively. Continued or early recurrent bleeding from varices occurred in 42 patients following sclerotherapy, an incidence of 5.6%. The incidence of recurrent variceal bleeding was much higher after emergency sclerotherapy (40/225; 18%) than following an elective session (2/519; 0.4%).
In the 42 patients who rebled following sclerotherapy the sclerosant had been administered intravariceally in 36 and paravariceally in 6 at the session preceding their recurrent haemorrhage. The volume of ethanolamine injected in patients who subsequently rebled (median 10, range 3-18 ml) was not significantly different from that administered to patients who did not rebleed (median 8.5, range 2-20 ml).
A continuous infusion of octreotide controlled persistent or recurrent variceal bleeding in 38/42 (90.5%) patients (Table 2 ). In four patients with severe liver disease (Child's C) bleeding was not controlled during the first 12 h of octreotide infusion as indicated by continued haematemesis and/or melaena accompanied by a systemic disturbance, and the need to In summary, the results of this study that octreotide is an effective treatment for post-injection sclerotherapy bleeding from oesophageal varices or ulcers and oesophagitis. These encouraging observations require confirmation in randomised controlled trials.
